ArticleClinical drug investigation2018

Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.

George Gourzoulidis et al.PubMed ↗Publisher ↗

No numbers read from the abstract.